Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 178

1.

Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition.

Köster F, Engel JB, Schally AV, Hönig A, Schröer A, Seitz S, Hohla F, Ortmann O, Diedrich K, Buchholz S.

Breast Cancer Res Treat. 2009 Jul;116(2):273-9. doi: 10.1007/s10549-008-0120-4. Epub 2008 Jul 16.

PMID:
18629632
2.

Inhibition of estrogen receptor positive and negative breast cancer cell lines with a growth hormone-releasing hormone antagonist.

Seitz S, Hohla F, Schally AV, Moder A, Engel JB, Horn F, Varga J, Zarandi M, Ortmann O, Köster F, Buchholz S.

Oncol Rep. 2008 Nov;20(5):1289-94.

PMID:
18949435
3.

Cellular mechanisms of growth inhibition of human endometrial cancer cell line by an antagonist of growth hormone-releasing hormone.

Zhao L, Yano T, Osuga Y, Nakagawa S, Oishi H, Wada-Hiraike O, Tang X, Yano N, Kugu K, Schally AV, Taketani Y.

Int J Oncol. 2008 Mar;32(3):593-601.

PMID:
18292936
4.

Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.

Heinrich E, Schally AV, Buchholz S, Rick FG, Halmos G, Mile M, Groot K, Hohla F, Zarandi M, Varga JL.

Prostate. 2008 Dec 1;68(16):1763-72. doi: 10.1002/pros.20843.

PMID:
18729085
5.

Activation of mitogen-activated protein kinases by a splice variant of GHRH receptor.

Barabutis N, Siejka A, Schally AV, Block NL, Cai R, Varga JL.

J Mol Endocrinol. 2010 Feb;44(2):127-34. doi: 10.1677/JME-09-0121. Epub 2009 Nov 6.

PMID:
19897610
6.

Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers.

Perez R, Schally AV, Vidaurre I, Rincon R, Block NL, Rick FG.

Oncotarget. 2012 Sep;3(9):988-97.

7.

Expression of growth hormone-releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers.

Plonowski A, Schally AV, Busto R, Krupa M, Varga JL, Halmos G.

Peptides. 2002 Jun;23(6):1127-33.

PMID:
12126741
8.

Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice.

Kahán Z, Varga JL, Schally AV, Rékási Z, Armatis P, Chatzistamou L, Czömpöly T, Halmos G.

Breast Cancer Res Treat. 2000 Mar;60(1):71-9.

PMID:
10845811
9.

Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.

Seitz S, Rick FG, Schally AV, Treszl A, Hohla F, Szalontay L, Zarandi M, Ortmann O, Engel JB, Buchholz S.

Oncol Rep. 2013 Jul;30(1):413-8. doi: 10.3892/or.2013.2435. Epub 2013 Apr 29.

PMID:
23624870
10.

Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer.

Papadia A, Schally AV, Halmos G, Varga JL, Seitz S, Buchholz S, Rick F, Zarandi M, Bellyei S, Treszl A, Szalontay L, Lucci JA.

Horm Metab Res. 2011 Oct;43(11):816-20. doi: 10.1055/s-0031-1287766. Epub 2011 Oct 18.

PMID:
22009378
11.

Stimulation of proliferation of MCF-7 breast cancer cells by a transfected splice variant of growth hormone-releasing hormone receptor.

Barabutis N, Tsellou E, Schally AV, Kouloheri S, Kalofoutis A, Kiaris H.

Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5575-9. Epub 2007 Mar 19.

12.

Expression of growth hormone-releasing hormone (GHRH) and splice variant of GHRH receptors in normal mouse tissues.

Christodoulou C, Schally AV, Chatzistamou I, Kondi-Pafiti A, Lamnissou K, Kouloheri S, Kalofoutis A, Kiaris H.

Regul Pept. 2006 Sep 11;136(1-3):105-8. Epub 2006 Jun 16.

PMID:
16781787
13.
14.

Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer.

Schally AV, Varga JL, Engel JB.

Nat Clin Pract Endocrinol Metab. 2008 Jan;4(1):33-43. Review.

PMID:
18084344
15.
16.

Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition.

Buchholz S, Seitz S, Schally AV, Engel JB, Rick FG, Szalontay L, Hohla F, Krishan A, Papadia A, Gaiser T, Brockhoff G, Ortmann O, Diedrich K, Köster F.

Int J Oncol. 2009 Oct;35(4):789-96.

PMID:
19724914
17.

Expression of Receptors for Pituitary-Type Growth Hormone-Releasing Hormone (pGHRH-R) in Human Papillary Thyroid Cancer Cells: Effects of GHRH Antagonists on Matrix Metalloproteinase-2.

Catanuto P, Tashiro J, Rick FG, Sanchez P, Solorzano CC, Glassberg MK, Block NL, Lew JI, Elliot SJ, Schally AV.

Horm Cancer. 2015 Jun;6(2-3):100-6. doi: 10.1007/s12672-015-0217-2. Epub 2015 Mar 10.

PMID:
25752763
18.

The effect of a novel antagonist of growth hormone releasing hormone on cell proliferation and on the key cell signaling pathways in nine different breast cancer cell lines.

Pozsgai E, Schally AV, Hocsak E, Zarandi M, Rick F, Bellyei S.

Int J Oncol. 2011 Oct;39(4):1025-32. doi: 10.3892/ijo.2011.1098. Epub 2011 Jun 23.

PMID:
21701777
19.

Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.

Föst C, Duwe F, Hellriegel M, Schweyer S, Emons G, Gründker C.

Oncol Rep. 2011 May;25(5):1481-7. doi: 10.3892/or.2011.1188. Epub 2011 Feb 17.

PMID:
21331448
20.

Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers.

Klukovits A, Schally AV, Szalontay L, Vidaurre I, Papadia A, Zarandi M, Varga JL, Block NL, Halmos G.

Cancer. 2012 Feb 1;118(3):670-80. doi: 10.1002/cncr.26291. Epub 2011 Jul 12.

Supplemental Content

Support Center